{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+infusion&page=13", "query": { "intervention": "Continuous infusion", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 2658, "total_pages": 266, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+infusion&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+infusion&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T05:00:55.898Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01086540", "title": "Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Sclerosis-Associated PAH" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "CMRI", "type": "DIAGNOSTIC_TEST" }, { "name": "prednisone", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "diphenhydramine", "type": "DRUG" }, { "name": "acetaminophen", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 57, "start_date": "2011-06-24", "completion_date": "2019-12-15", "has_results": true, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-10-20T05:00:55.898Z", "location_count": 17, "location_summary": "Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01086540" }, { "nct_id": "NCT06626516", "title": "Tebentafusp-tebn With LDT in Metastatic UM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "Tebentafusp-Tebn", "type": "DRUG" }, { "name": "GM-CSF (Sargramostim)", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2025-10-15", "completion_date": "2032-08", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-20T05:00:55.898Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06626516" }, { "nct_id": "NCT06801834", "title": "Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer (ES-SCLC)" ], "interventions": [ { "name": "Sacituzumab Govitecan (SG)", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Amrubicin (Japan only)", "type": "DRUG" }, { "name": "Lurbinectedin (regions/countries where approved and available)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 695, "start_date": "2025-04-04", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-20T05:00:55.898Z", "location_count": 23, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • Anaheim, California + 19 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Hinsdale", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06801834" }, { "nct_id": "NCT00621816", "title": "Sodium Nitroprusside for Blood Pressure Reduction in the ICU (SNP2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "nitroprusside", "type": "DRUG" }, { "name": "placebo infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Day to 17 Years" }, "enrollment_count": 45, "start_date": "2009-01", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2011-12-06", "last_synced_at": "2026-10-20T05:00:55.898Z", "location_count": 8, "location_summary": "Little Rock, Arkansas • Stanford, California • Louisville, Kentucky + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Stanford", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00621816" }, { "nct_id": "NCT00597714", "title": "Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin's Disease", "Non Hodgkin's Lymphoma", "Myeloma", "Leukemia", "Myelodysplasia" ], "interventions": [ { "name": "Non-myeloablative Stem Cell Transplantation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Rizzieri, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 264, "start_date": "2008-02", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2014-06-02", "last_synced_at": "2026-10-20T05:00:55.898Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00597714" }, { "nct_id": "NCT03767335", "title": "MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "MEN1611", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Menarini Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2018-11-13", "completion_date": "2024-02-23", "has_results": true, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-10-20T05:00:55.898Z", "location_count": 3, "location_summary": "Fort Lauderdale, Florida • Farmington Hills, Michigan • St Louis, Missouri", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03767335" }, { "nct_id": "NCT03712787", "title": "An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Tilavonemab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "57 Years", "maximum_age": "88 Years", "sex": "ALL", "summary": "57 Years to 88 Years" }, "enrollment_count": 364, "start_date": "2019-03-22", "completion_date": "2021-09-30", "has_results": true, "last_update_posted_date": "2022-09-22", "last_synced_at": "2026-10-20T05:00:55.898Z", "location_count": 32, "location_summary": "Phoenix, Arizona • Irvine, California • La Jolla, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Delray Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03712787" }, { "nct_id": "NCT04729387", "title": "Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 358, "start_date": "2021-07-22", "completion_date": "2026-01-19", "has_results": true, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-20T05:00:55.898Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Fort Myers, Florida • West Palm Beach, Florida + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729387" }, { "nct_id": "NCT02281084", "title": "Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Oral Azacitidine", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-07-06", "completion_date": "2023-09-14", "has_results": true, "last_update_posted_date": "2024-10-04", "last_synced_at": "2026-10-20T05:00:55.898Z", "location_count": 23, "location_summary": "New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02281084" }, { "nct_id": "NCT01409278", "title": "Local Anesthetic Infiltration and Infusion for Pain Control After Hip Replacement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Osteoarthritis" ], "interventions": [ { "name": "Ropivacaine infiltration and saline infusion.", "type": "PROCEDURE" }, { "name": "Ropivacaine infiltration and infusion.", "type": "PROCEDURE" }, { "name": "Normal Saline", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Trinity Health Of New England", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 105, "start_date": "2009-08", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2011-08-04", "last_synced_at": "2026-10-20T05:00:55.898Z", "location_count": 1, "location_summary": "Hartford, Connecticut", "locations": [ { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01409278" } ] }